<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02583828</url>
  </required_header>
  <id_info>
    <org_study_id>LET+CTX</org_study_id>
    <nct_id>NCT02583828</nct_id>
  </id_info>
  <brief_title>Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized clinical trial to investigate the efficacy of letrozole combined with
      metronomic oral cyclophosphamide in elderly metastasis breast cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival(PFS) of the subjects</measure>
    <time_frame>up to approximately 2 years</time_frame>
    <description>Time from the randomization date to the start of disease progression or subject death from any cause (progression assessed by investigator using Response Evaluation Criteria in Solid Tumors 1.1for elderly metastatic breast cancer subjects).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of each treatment regimen for the subjects</measure>
    <time_frame>up to approximately 2 years</time_frame>
    <description>Assessment based on Adverse Events (AEs) , Serious Adverse Events (SAEs), laboratory abnormalities in subjects .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the quality of life for the subjects in the each treatment regimen</measure>
    <time_frame>up to approximately 2 years</time_frame>
    <description>Subjects complete questionnaire in every 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare disease control rate for the subjects</measure>
    <time_frame>up to approximately 2 years</time_frame>
    <description>Complete response (CR), Partial response (PR), and Stable Disease (SD) more than or equal to 8 weeks.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in this arm will receive cyclophosphamide 50 mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide plus letrozole for resistant patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in the this will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide plus letrozole for treat-naive patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>letrozole alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive letrozole 2.5 mg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide 50mg</intervention_name>
    <arm_group_label>Cyclophosphamide alone</arm_group_label>
    <arm_group_label>Cyclophosphamide plus letrozole for resistant patients</arm_group_label>
    <arm_group_label>Cyclophosphamide plus letrozole for treat-naive patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole 2.5 mg</intervention_name>
    <arm_group_label>Cyclophosphamide plus letrozole for resistant patients</arm_group_label>
    <arm_group_label>Cyclophosphamide plus letrozole for treat-naive patients</arm_group_label>
    <arm_group_label>letrozole alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed metastatic breast cancers patients with estrogen receptor
             positive and/or progesterone receptor positive;

          -  Elderly women (age â‰¥ 65years)

          -  Failure or relapse from standard chemotherapy or unfit for chemotherapy

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors(RECIST);

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

          -  Adequate bone marrow, liver and renal function;

          -  Estimated life expectancy of at least 3 months.

        Exclusion Criteria:

          -  Serious or uncontrolled concurrent medical illness

          -  Uncontrolled primary and metastatic brain tumor

          -  History of second primary malignancies

          -  Having been enrolled in other clinical trials within a month
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Ren, MD,PhD</last_name>
    <phone>6810-63926317</phone>
    <email>renjun9688@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Ren, MD, PhD</last_name>
      <phone>86-10-63926317</phone>
      <email>renjun9688@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Jun Ren MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

